Early, Deep, and Durable Responses, and Low Rates of Cytokine Release Syndrome With REGN5458, a BCMAxCD3 Bispecific Antibody, in a Phase 1/2 First-In-Human Study in Patients With Relapsed/Refractory Multiple Myeloma

Jeffrey A. Zonder,Joshua Richter,Naresh Bumma,Jason Brayer,James E. Hoffman,William I. Bensinger,Ka Lung Wu,Linzhi Xu,Dhruti Chokshi,Anita Boyapati,Damien Cronier,Yariv Houvras,Karen Rodriguez Lorenc,Glenn S. Kroog,Madhav V. Dhodapkar,Suzanne Lentzsch,Dennis Cooper,Sundar Jagannath

Clinical Lymphoma Myeloma and Leukemia（2022）

引用 0|浏览7

暂无评分

摘要

REGN5458 shows early, deep, and durable responses with a manageable safety profile in triple or greater-refractory patients with RRMM. This study is funded by Regeneron.

查看译文

关键词

MM,clinical trial,bispecific antibody,multiple myeloma,Phase I/II

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要